A Trial to Learn if Having ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
Conditions: Nonalcoholic Steatohepatitis; Genetic Risk Factor Interventions: Drug: ALN-PNP Dose Level 1; Drug: ALN-PNP Dose Level 2; Drug: ALN-PNP Dose Level 3; Drug: Matching Placebo Sponsor: Regeneron Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials